Meridigen Biotech Co., Ltd.   Report issue

For profit Phase 1
Founded: Taipei Taiwan (2011)

Organization Overview

First Clinical Trial
2018
NCT03631420
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Meridigen Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (2)

umbilical cord mesenchymal stem cells (4 trials)

umc119-06-05 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Bronchopulmonary Dysplasia (Phase 1)

Cerebral Infarction (Phase 1)

Ischemia (Phase 1)

Lung Diseases (Phase 1)

Lung Diseases, Obstructive (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Respiratory Distress Syndrome (Phase 1)

Respiratory Distress Syndrome, Newborn (Phase 1)

Stroke (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 6
  • # of Trial APIs: 2